Delving into the Latest Updates on Xenova Group Plc with Synapse

概览

疾病领域	数量

感染	1
肿瘤	1

排名前五的药物类型	数量

重组亚单位疫苗	1

排名前五的靶点	数量

HPV E6 x HPV E7 x HPV L2	1

关联

15

项与 Xenova Group Plc 相关的药物

Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

靶点

HPV E6 x HPV E7 x HPV L2

作用机制

HPV E6抑制剂 [+3]

在研机构

Cancer Research Technology Ltd. [+3]

原研机构

Xenova Ltd.

在研适应症

外阴肿瘤 [+1]

非在研适应症

子宫颈发育不良 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

XR-304

靶点-

作用机制-

在研机构-

原研机构

Xenova Group Plc

在研适应症-

非在研适应症

溃疡性结肠炎

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

XR-9019

靶点-

作用机制-

在研机构-

原研机构

Xenova Group Plc

在研适应症-

非在研适应症

肿瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Xenova Group Plc 相关的临床结果

登录后查看更多信息

0 项与 Xenova Group Plc 相关的专利（医药）

登录后查看更多信息

10

项与 Xenova Group Plc 相关的文献（医药）

2004-07-15·Journal of Clinical Oncology

Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine or docetaxel

作者: Riches, S. ; Fox, E. ; Fojo, T. ; Widemann, B. C. ; Balis, F. M. ; Norris, D. ; Van Tellingen, O. ; Chen, C. C. ; Boniface, G. ; Bates, S.

2003-08-15·The Journal of Immunology2区 · 医学

Plasminogen Activator Inhibitor-1 Supports IL-8-Mediated Neutrophil Transendothelial Migration by Inhibition of the Constitutive Shedding of Endothelial IL-8/Heparan Sulfate/Syndecan-1 Complexes

2区 · 医学

Article

作者: Marshall, Lindsay J. ; Shute, Janis K. ; Ramdin, Lara S. P. ; Brooks, Teresa ; DPhil, Peter Charlton

AbstractThe endothelium is the primary barrier to leukocyte recruitment at sites of inflammation. Neutrophil recruitment is directed by transendothelial gradients of IL-8 that, in vivo, are bound to the endothelial cell surface. We have investigated the identity and function of the binding site(s) in an in vitro model of neutrophil transendothelial migration. In endothelial culture supernatants, IL-8 was detected in a trimolecular complex with heparan sulfate and syndecan-1. Constitutive shedding of IL-8 in this form was increased in the presence of a neutralizing Ab to plasminogen activator inhibitor-1 (PAI-1), indicating a role for endothelial plasminogen activator in the shedding of IL-8. Increased shedding of IL-8/heparan sulfate/syndecan-1 complexes was accompanied by inhibition of neutrophil transendothelial migration, and aprotinin, a potent plasmin inhibitor, reversed this inhibition. Platelets, added as an exogenous source of PAI-1, had no effect on shedding of the complexes or neutrophil migration. Our results indicate that IL-8 is immobilized on the endothelial cell surface through binding to syndecan-1 ectodomains, and that plasmin, generated by endothelial plasminogen activator, induces the shedding of this form of IL-8. PAI-1 appears to stabilize the chemoattractant form of IL-8 at the cell surface and may represent a therapeutic target for novel anti-inflammatory strategies.

2003-03-01·Journal of General Virology3区 · 医学

Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus

3区 · 医学

Article

作者: Tsitoura, E. ; Klenerman, P. ; Lucas, M. ; Mavromara, P. ; Entwisle, C. ; Kouvatsis, V. ; Aslanoglou, E. ; Laliotou, B. ; Hadziyannis, A. ; Montoya, M. ; Miller, J. ; Hadziyannis, S. ; Borrow, P.

A replication-defective herpes simplex virus type 1 (HSV-1) recombinant lacking the glycoprotein H (gH)-encoding gene and expressing a truncated form of the hepatitis C (HCV) E2 glycoprotein (E2-661) was constructed and characterized. We show here that cells infected with the HSV/HCV recombinant virus efficiently express the HCV E2-661 protein. Most importantly, cellular and secreted E2-661 protein were both readily detected by the E2-conformational mAb H53 and despite the high expression levels, only limited amounts of misfolded aggregates were detected in either the cellular or secreted fractions. Furthermore, cell-associated and secreted E2-661 protein bound to the major extracellular loop (MEL) of CD81 in a concentration-dependent manner and both were highly reactive with sera from HCV-infected patients. Finally, BALB/c mice immunized intraperitoneally with the recombinant HSV/HCV virus induced high levels of anti-E2 antibodies. Analysis of the induced immunoglobulin G (IgG) isotypes showed high levels of IgG2a while the levels of the IgG1 isotype were significantly lower, suggesting a Th1-type of response. We conclude that the HSV-1 recombinant virus represents a promising tool for production of non-aggregated, immunologically active forms of the E2-661 protein and might have potential applications in vaccine development.

100 项与 Xenova Group Plc 相关的药物交易

登录后查看更多信息

100 项与 Xenova Group Plc 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

14

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Human papillomavirus vaccine TA-CIN(Xenova Ltd.) ( HPV E6 x HPV E7 x HPV L2 )	人乳头瘤病毒 16 阳性更多	临床前
XR-9051 ( P-gp )	肿瘤更多	终止
XR-9019	肿瘤更多	终止
XR-168 ( Collagenase )	类风湿关节炎更多	终止
XR-1500	肿瘤更多	终止